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Objective: To examine the relationship between early renal duplex sonography (RDS) and restenosis after primary renal
artery percutaneous angioplasty and stenting (RA-PTAS).
Methods:Consecutive patients undergoing RA-PTAS for hemodynamically significant atherosclerotic renal artery stenosis
with hypertension and/or ischemic nephropathy between September 2003 and July 2010 were identified from a
prospective registry. Patients had renal RDS pre–RA-PTAS, within 1 week of RA-PTAS and follow-up RDS examina-
tions after the first postoperative week for surveillance of restenosis. Restenosis was defined as a renal artery peak systolic
velocity (PSV) >180 cm/s on follow-up RDS. Associations between RDS and restenosis were examined using
proportional hazards regression.
Results: Eighty-three patients (59% female; 12% nonwhite; mean age, 70  10 years; mean pre–RA-PTAS PSV, 276  107
cm/s) undergoing 91 RA-PTAS procedures comprised the sample for this study. All procedures included a completion
arteriogram demonstrating no significant residual stenosis. Mean follow-up time was 14.9 10.8 months. Thirty-four renal
arteries (RAs) demonstrated restenosis on follow-up with a median time to restenosis of 8.7 months. There was no significant
difference in the mean PSV pre–RA-PTAS in those with and without restenosis (287  96 cm/s vs 269  113 cm/s; P 
.455), and PSV pre–RA-PTAS was not predictive of restenosis. Within 1 week of RA-PTAS, mean renal artery PSV differed
significantly for renal arteries with and without restenosis (112 27 cm/s vs 91 34 cm/s; P .003). Proportional hazards
regression analysis demonstrated increased PSV on first post–RA-PTAS RDS was significantly and independently associated
with subsequent restenosis during follow-up (hazard ratio for 30 cm/s increase, 1.81; 95% confidence interval, 1.32-2.49; P
 .0003). There was no difference in pre- minus postprocedural PSV in those with and without restenosis on follow-up (175
 104 cm/s vs 179  124 cm/s; P  .88), nor was this associated with time to restenosis. Best subsets model selection
identified first postprocedural RDS as the only factor predictive of follow-up restenosis. A receiver-operating characteristic
curve was examined to assess the first week PSV post–RA-PTASmost predictive of restenosis during follow-up. The ideal cut
point for RA-PSV was 87 cm/s or greater. This value was associated with a sensitivity of 82.4%, specificity of 52.6%, and area
under the receiver-operating characteristic curve of 69.3%. Increased first postprocedural RA-PSV was predictive of lower
estimated glomerular filtration rate in the first 2 years after the procedure (1.6  0.7 mL/min/1.73 m2 lower estimated
glomerular filtration rate per 10 cm/s increase in RA-PSV; P  .010).
Conclusions: Early renal artery PSV within 1 week after RA-PTAS predicted renal artery restenosis and lower postprocedure
renal function. Recurrent stenosis demonstrated no associationwith absolute elevation in PSVprior toRA-PTASnorwith the
change in PSV after RA-PTAS. These data suggest that detectable differences exist in renal artery flow parameters following
RA-PTAS that are predictive of restenosis during follow-up but are not apparent on completion arteriography or detectable
by intra-arterial pressure measurements. Further study is warranted. (J Vasc Surg 2012;56:1373-80.)
e
A
c
t
P
e
a
n
a
r
R
U
c
a
r
r
o
hDespite the lack of level I evidence favoring improved
patient survival free from adverse cardiac and vascular
events, the use of percutaneous renal artery angioplasty and
stenting (RA-PTAS) for atherosclerotic renovascular dis-
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http://dx.doi.org/10.1016/j.jvs.2012.05.067ase has increased exponentially over the past 15 years.
mong Medicare beneficiaries, claims for RA-PTAS in-
reased 2.4-fold in the year 2000 compared with 1996.1 In
he Southeast, the number of Medicare claims for RA-
TAS increased 1400% in this period.1 Currently, it is
stimated that 35,000 RA-PTAS are performed annually
mongMedicare beneficiaries.2 As the population ages, the
umber of procedures is likely to grow.
In part, this increase in procedural volumes is attribut-
ble to advances in materials and techniques. Contempo-
ary reports frequently cite a 98% technical success rate for
A-PTAS when defined by completion angiography.3,4
nfortunately, technical success does not uniformly ensure
linical benefit (ie, improved blood pressure control
nd/or increased excretory renal function).3,5-8 Moreover,
ecurrent stenosis at 6 months after RA-PTAS has been
eported in 17% to 50% of renal arteries (RAs) treated for
stial atherosclerosis.4,9-14 Early restenosis after RA-PTAS
as demonstrated significant associations with RA diame-
er,12,15 stent diameter,16 body mass index,17 smoking,18
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November 20121374 Christie et aland preprocedural use of statins.19 Conceivably, rates of
early restenosis approaching 50% may limit the clinical
benefit of RA-PTAS.
Renal duplex sonography (RDS) has proven clinically
useful as a screening method for native RA disease,20 as an
intraoperative completion study21 and as amethod to evaluate
postoperative patency after open operative repair.22 Recently,
RDS parameters correlating with restenosis after RA-PTAS
have also been defined.23 This retrospective study examines
the association betweenDoppler estimates of (RA) bloodflow
velocity fromRDSperformedwithin 1week of RA-PTAS and
restenosis during follow-up.
METHODS
Study population. This review was performed with
the approval of the Wake Forest Baptist Health Institu-
tional Review Board. Consecutive primary RA-PTAS pro-
cedures performed between September 2003 and July
2010 for atherosclerotic RA stenosis in patients with severe
hypertension and/or renal dysfunction were identified
from a prospective registry of renovascular procedures. All
lesions were ostial in location at or about the origin of the
RA, and all were high grade representing60% stenosis on
arteriography. All patients had the indication of severe
multidrug hypertension or observed decreases in renal
function manifested by decreasing estimated glomerular
filtration rate or increasing creatinine. Each ostial stenosis
was treated with primary endoluminal stenting. Patients
with RA-PTAS performed for nonostial stenosis, restenosis
of previously stented atherosclerotic disease or for treat-
ment of fibromuscular dysplasia were excluded. All proce-
dures were performed by vascular surgeons at the Wake
Forest Baptist Medical Center between September 2003
and July 2010. Standard preparation, procedural manage-
ment, and follow-up for patients treated with RA-PTAS at
our center have been described previously.3,24 RDS was
performed at baseline prior to RA-PTAS and within 1 week
after RA-PTAS. Routine RDS surveillance was conducted
at 1-month and 6-month intervals after primary interven-
tion.
Data collection and management. Clinical data, in-
cluding patient demographics, comorbidities, and labora-
tory results were retrospectively collected from the elec-
tronic medical record. RDS data, including peak systolic
and end-diastolic velocities, resistive index, acceleration
time, and kidney length were collected from a prospectively
maintained clinical vascular laboratory database.
Renal angiography. RA-PTAS procedures were per-
formed using digital subtraction angiography (DSA) with
the Seimens Axiom Artix (Malvern, Pa). DSA was obtained
with power injection through a pigtail catheter placed at
the level of the RAs. Balloon-mounted stents were used in
all patients and sized to match the diameter of the distal,
normal-caliber (RA) as measured by angiography at the
time of treatment, while ensuring areas of poststenotic
dilatation were not used for sizing. In 23 of 91 interven-
tions, arterial pullout pressures were documented after
RA-PTAS to identify residual pressure gradients. Postpro- dessing of digital subtraction angiograms was performed by
wo registered radiology technologists and transferred to
he electronic medical record.
Renal duplex sonography. Renal arteries were sur-
eilled for restenosis during follow-up using RDS. Prepa-
ation and performance of RDS at our center has been
escribed previously.20 Patients underwent routine RDS
xaminations within 1 week of treatment, 1 month postin-
ervention, and then at 6-month intervals. RDS studies
ere performed using either a Phillips IU22 (Philips
ealthcare, Andover, Mass; C5-1 probe), ATL HDI 5000
Advanced Technology Laboratories, Bothwell, Wash;
5-2 probe), or GE Logiq E9 (General Electric Health-
are, Waukesha, Wisc; C1-5 probe) ultrasound system.
estenosis was defined as RA-peak systolic velocity (PSV)
180 cm/s, which corresponds to a 60% diameter reduc-
ion. This RDS criterion for restenosis has been used by
thers25-27 and has been internally validated at our cen-
er.19 RA-PSV  180 cm/s at the first postintervention
tudy was considered residual stenosis, and those cases were
xcluded from further analysis.
Statistical analysis. Descriptive statistics (means and
Ds of continuous variables, frequencies and percentages of
ichotomous variables) were calculated for preoperative
edical conditions, blood pressures, medication use, renal
unction, demographics, and RDS parameters. Univariable
ssociations between factors in patients with and without
ollow-up restenosis were assessed using t-tests for contin-
ous variables and 2 tests or Fisher exact test (if one or
ore expected cell counts was less than five) for dichoto-
ous variables. Time to restenosis and postoperative sur-
ival were estimated using the Kaplan-Meier product-limit
stimate. Multivariable predictors of RA restenosis were
xamined using proportional hazards regression models
ith a robust sandwich estimate of the covariance matrix28
o account for clustered observations in patients with bilat-
ral repair. For each outcome, multivariable model selec-
ion was performed using best subsets regression where all
odels with six predictors or less, ordered by significance of
lobal score 2 statistics, were considered. A final model
as chosen with the smallest value for the Akaike informa-
ion criterion and all covariates included were significant at
he 5% alpha level. Evaluation of an optimal cut point in
ostprocedural RDS parameters to identify arteries at risk
f restenosis was performed using receiver-operating char-
cteristic (ROC) curve analysis, which selects the point that
aximizes the sum of sensitivity and specificity. Distribu-
ions of RDS parameters between restenosis and no reste-
osis groups were compared using box-and-whisker plots.
omparison of postrepair changes in blood pressure, num-
er of antihypertensive medications and estimated glomer-
lar filtration rate (GFR) between groups with and without
estenosis over the first 24 months of follow-up was per-
ormed usingmaximum-likelihood repeatedmeasures anal-
sis of covariance with a compound-symmetric covariance
tructure to account for within-patient correlation. Models
ere fitted for each outcome (systolic blood pressure [SBP],
iastolic blood pressure [DBP], number of medications, and
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Volume 56, Number 5 Christie et al 1375estimated glomerular filtration rate [eGFR]), which included
the preoperative value as well as the first postrepair PSV as
continuous covariates. All analyseswere performedusing SAS,
version 9.3 software (SAS Institute, Inc, Cary, NC).
RESULTS
RA-PTASwas performed on 175 RAs in 155 patients at
Wake Forest Baptist Medical Center during the study pe-
riod. Of these, 28 secondary RA-PTAS of restenosis were
excluded. Of the remaining procedures, 36 without RDS
within 1 week of primary RA-PTAS; 10 with early postpro-
cedural PSV 180 cm/s; and 10 that did not have RDS
performed after the first weekwere excluded. The final sample
consisted of 91 RAs treated with RA-PTAS in 83 patients. All
treatments were primary angioplasty and stenting procedures.
After RA-PTAS, a zero pressure gradient was measured in 22
of 23 arteries. RDS was performed the day of RA-PTAS in 65
patients, on postprocedure day 1 in 24 patients and from 2 to
7 days in the remaining two arteries.
Thirty-two of 83 patients (39%) had 34 RAs that pro-
gressed to restenosis over a mean follow-up of 14.9 10.8
months. The median time to restenosis was 8.7 months. All
of the pressure measurements obtained in patients that
developed restenosis demonstrated zero gradient. Patient
characteristics with and without follow-up restenosis are
shown in Table I. Only preoperative creatinine (1.3  0.4
vs 1.6  0.6 in patients with and without restenosis; P 
.019) and bilateral repair (0% vs 13.7%, in patients with and
Table I. Patient demographics (n  83)a
Variable
(mean  SD or frequency %)
Overal
(n  83
Age (years) 70.0  9
Black 10 (12.
Female 49 (59.
Duration of hypertension (m)b 181  1
Highest pre-op SBP (mm Hg) 196  2
Highest pre-op DBP (mm Hg) 100  2
Number of HTN meds pre-op 2.8  1
Serum creatinine pre-op (mg/dL) 1.5  0
Estimated GFR (mL/min/1.73 m2) 51.1  2
Renal insufficiency pre-op (Cr 1.3) 47 (56.
On dialysis pre-op 0 (0.0
Statin 55 (66.
Aspirin 64 (77.
Clopidogrel 19 (22.
History of CHF 6 (7.2
History of MI or angina 26 (31.
History of coronary artery disease 31 (37.
History of TIA/CVA 16 (19.
History of diabetes mellitus 20 (24.
History of LVH 30 (36.
Abdominal aortic aneurysm 7 (8.4
Bilateral procedure 7 (8.4
CHF, Congestive heart failure; CVA, cerebrovascular accident;DBP, diastol
ventricular hypertrophy; MI, myocardial infarction; SBP, systolic blood pres
aAll variables except dialysis dependence and bilateral procedure were candi
bn  74 (no duration data available on 10 patients), 29 with patency failure
cP  .05 for test of difference between stenosis and no restenosis.without restenosis; P  .040 by Fisher exact test) demon- atrated significant association with restenosis. Kidney-based
uplex characteristics, including preprocedural PSV, PSV
ithin 1 week of the RA-PTAS, and pre- minus first post-
rocedural PSV changes were examined (Table II). There
as no significant difference in the mean PSV pre–RA-
TAS in those with and without restenosis on follow-up
287  96 cm/s vs 269 113 cm/s; P  .455), pre- to
ostprocedural change in PSV (175  104 cm/s vs 179 
21 cm/s; P  .891), or stent length (15.9  5.1 mm vs
5.6 3.8mm; P .692); however, initial RA-PSVwithin
week of RA-PTAS was strongly associated with restenosis
112  27cm/s with restenosis vs 91  34 cm/s without
estenosis; P  .003), as was mean stent diameter (5.4 
.8mmwith restenosis vs 5.7 0.8 without restenosis; P
045). An ROC curve to determine the optimal early PSV
ssociated with RA restenosis after RA-PTAS is presented
n Fig 1. The identified cut point was RA-PSV of 87 cm/s
r greater, which was associated with a sensitivity of 82.4%,
pecificity of 52.6%, and area under the ROC curve of
9.3%. Box-and-whisker plots showing the distributions of
nitial RA-PSV in patients with and without restenosis are
resented in Fig 2. The distribution of velocities in the
roup without restenosis was broad; however, the median
nitial RA-PSV for those with restenosis fell above the 75th
ercentile of the RA-PSV without a restenosis.
Product-limit estimates of time to restenosis are shown
n Fig 3. At the 12-month follow-up, 34% of arteries
xhibited restenosis. Increased early RA-PSV demonstrated
Restenosis No restenosis
(n  32) (n  51)
68.9  10.5 70.7  9.6
4 (12.5) 6 (11.8)
22 (68.8) 27 (52.9)
131  104c 213  216c
201  27 192  29
101  19 100  26
3.0  1.1 2.7  1.1
1.3  0.4c 1.6  0.6c
53.8  18.6 49.4  26.4
14 (43.8) 33 (64.7)
0 (0.0) 0 (0.0)
21 (65.6) 34 (66.7)
26 (81.3) 38 (74.5)
8 (25) 11 (21.6)
2 (6.3) 4 (7.8)
9 (28.1) 17 (33.3)
23 (71.9) 29 (56.9)
7 (21.9) 9 (17.6)
8 (25.0) 12 (23.5)
13 (40.6) 17 (33.3)
1 (3.1) 6 (11.8)
0 (0.0)a 7 (13.7)a
d pressure; GFR, glomerular filtration rate;HTN, hypertension; LVH, left
D, standard deviation; TIA, transient ischemic attack.
or multivariate model.
ithout patency failure.l
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November 20121376 Christie et alsis in proportional hazards regression analysis (hazard ratio
for 30 cm/s increase, 1.81; 95% confidence interval [CI],
1.32-2.49; P  .0003). Early RA-PSV was the only factor
selected as a significant predictor of restenosis in best
subsets regression analysis; however, bilateral repair was
significantly associated with lack of restenosis in univariate
analysis (Table I). Bilateral repair was excluded as a candi-
date variable because no restenosis events occurred in the
bilateral group resulting in an inestimable hazard ratio.
Data on blood pressure, antihypertensive medication
use, and renal function during the first 24 months postpro-
cedure are presented in Table III. Longitudinal data were
available for at least one parameter on 76 patients. No
Table II. RA-PSV estimated by duplex ultrasound in kidn
Duplex study
Resten
n
Preoperative PSV (cm/s) 34
First postoperative PSV (cm/s) 34
Pre-op – postop PSV difference (cm/s) 34
Stent diameter (mm) 34
Stent length (mm) 34
PSV, Peak systolic velocity; RA, renal artery; SD, standard deviation.
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Fig 1. Receiver-operating characteristic (ROC) curve fo
artery peak systolic velocity (RA-PSV). Optimal cut poinrelationships were observed between presence of restenosis nr first postprocedure RA-PSV and blood pressures or
umber of medications. Patients with restenosis had signif-
cantly higher average eGFR (64.8  3.0 mL/min/1.73
2 vs 49.1  2.3 mL/min/1.73 m2; P  .001) after
ontrolling for preprocedure eGFR; however, first postpro-
edure RA-PSV, included as a continuous covariate in
egression models, was associated with lower average eGFR
1.6  0.7 mL/min/1.73 m2 lower eGFR per 10 cm/s
ncrease in RA-PSV; P  .010).
ISCUSSION
Increased RA-PSV from early RDS performed within 1
eek of RA-PTAS was associated with recurrent RA reste-
ith and without follow-up restenosis
No restenosis
P value SD n Mean  SD
 96 55 269  113 .455
 27 57 91  34 .003
104 55 179  121 .878
 0.8 57 5.7  0.8 .045
 5.1 57 15.6  3.8 .692
cificity
5 0.6 0.7 0.8 0.9 1.0
enosis in 91 renal arteries using first postprocedural renal
cm/s) is noted on the figure.eys w
osis
Mean
287
112
175
5.4
15.9- Spe
0.
r restosis on follow-up, as well as lower postprocedure eGFR.
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Volume 56, Number 5 Christie et al 1377Unfortunately, analysis failed to define a critical postproce-
dural RA-PSV value that accurately predicted all restenosis
on follow-up; however, each 30 cm/s increase in RA-PSV
increased the absolute risk of restenosis by 1.8-fold. This
association between early postprocedural RA-PSV and re-
stenosis was significant and independent of all other RDS
parameters both before and after RA-PTAS.
A recent report has described a similar relationship
between parameters defined by early postprocedural RDS
after RA-PTAS and follow-up restenosis.29 Thalhammer
and colleagues examined restenosis after PTAS in 105 RAs
among 87 patients. In this prospective, observational study,
RDS parameters were estimated prior to RA-PTAS, at 1 day
and 6 month after intervention. These authors observed a
16.8% restenosis at 6-month follow-up. By logistic and
linear stepwise regression analysis, RA-PSV 1 day after
PTAS demonstrated a significant and independent associa-
tion with restenosis (1.4 0.4 m/s vs 1.0 0.3 m/s; P
.002). On the basis of these findings, the investigators
recommended early RDS to define patients at risk for early
restenosis after RA-PTAS.
The current report describes early RDS after RA-PTAS
and its relationship to restenosis. Several authors have
suggested that intraoperative duplex ultrasound comple-
tion studies and postprocedure surveillance are worthwhile
after arterial interventions.21,22,30 Normal duplex studies
after arterial interventions confirm the absence of technical
error, predict early clinical success, and establish a baseline
for subsequent surveillance studies. Surveillance duplex
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Fig 2. Box and whisker plot representing the distribution of
initial renal artery peak systolic velocity (RA-PSV). Top aspect of box
represents 75th percentile level for group, horizontal line within
box represents median, dot represents mean, and lower aspect of box
represents the 25th percentile level. The whiskers extend from the
25th or 75th percentile to the extreme of 1.5 interquartile ranges.ultrasound has found utility after carotid endarterectomy pnd stenting,31 iliac stenting,32 peripheral bypass and stent-
ng,33,34 as well as renal and mesenteric bypass and stent-
ng.23,35 For each procedure, specific criteria have been
roposed to identify clinically significant lesions at risk for
hrombosis as well as procedure-specific adverse events. In
hese instances, duplex ultrasound has been used to identify
failing intervention to guide secondary procedures in
opes of providing assisted patency. By contrast, the expe-
ience described herein used early RDS to identify RA-
TAS at risk for follow-up restenosis despite normal tradi-
ional measures of assessment at completion, ie, completion
ngiography and intra-arterial pressure measurements.
The potential value of early RDS after RA-PTAS and its
ssociation with restenosis resides with the clinical conse-
uence of the failed procedure and efficacy of secondary
ntervention. Although data regarding the benefit of primary/
econdary RA-PTAS and clinical consequences of failed
A-PTAS are lacking, experience with failed operative re-
airs suggests that secondary procedures may be associated
ith significant adverse clinical consequences.36 Of 454
atients with RA atherosclerosis managed with open oper-
tive repair at our center, 13 patients required reoperation
or recurrent hypertension and/or renal insufficiency.
wenty-one failed repairs (nine occlusions; 12 restenoses)
ere observed among these 13 patients, and each failed
epair underwent a secondary intervention (five nephrecto-
ies; five RA-PTAS; 11 secondary operative repairs). Al-
hough 95% of patients demonstrated beneficial blood
ressure response after secondary intervention (15% cured;
0% improved), only one patient demonstrated increased
xcretory renal function. Regardless of the type of failure
stenosis vs thrombosis) or the method of secondary inter-
ention, failure of primary operative intervention demon-
trated significant and independent association with even-
ual dialysis dependence and follow-up death. Should
ecurrent stenosis after primary RA-PTAS demonstrate
imilar associations, duplex ultrasound may have clinical
tility as a completion study combined with angiography
nd intra-arterial pressure measurements. Whether follow-
p restenosis rates after RA-PTAS can be improved by
he use of intravascular ultrasound and subsequent addi-
ional balloon angioplasty guided by completion RDS at
he initial intervention is unknown, but the concept is
ntriguing and is currently under investigation at our
nstitution.
The association betweenRA-PSVderived fromearlyRDS
nd restenosis despite normal completion angiography and
bsent arterial pressure gradients is unexplained but may re-
ect limitations in these traditional assessments. Temporal
igital subtraction angiography used in this report may over-
stimate lumen dimension after RA-PTAS especially when
ostprocessing uses peak opacification and pixel shift func-
ions.37 Retrospectivemisregistration artifacts likely occur and
ay overestimate lumen diameters after placement of an in-
raluminal stent. Moreover, criteria for a significant transle-
ional pressure gradient after RA-PTAS (eg, 10-12 mm Hg)
equire a significant cross-sectional lumen reduction that ap-
roximates 75%. These limitations of completion digital sub-
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November 20121378 Christie et altraction angiography and arterial pressure gradient measure-
ments highlight the need for improved methods of technical
assessment after RA-PTAS.
Estimated rates of recurrent RA stenosis at 6 and 12
months (40% and 56%, respectively) seem most consistent
with neointimal fibrous hyperplasia rather than secondary
progression of atherosclerosis,19 and those who were stud-
ied angiographically appeared to have restenosis through-
out the stent consistent with a hyperplastic response. Al-
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Fig 3. Product-limit estimates for renal artery (RA) res
(PTAS) (34 failures, 91 arteries). The standard error of t
Table III. Blood pressures, antihypertensive medications,
follow-up restenosis
Postrepair response
Restenos
n M
Systolic BP (mm Hg) 28 144
Diastolic BP (mm Hg) 26 67
Number of antihypertensive meds 28 2.7
Estimated GFR (mL/min/1.73 m2) 26 64
BP, Blood pressure; GFR, glomerular filtration rate; SE, standard error.though the pathobiology of neointimal hyperplasia and its helationship to blood flow velocity are incompletely under-
tood, it would seem plausible that Doppler-derived mea-
ures consistent with flow disturbance could favor hyper-
lasia.19
Besides the limitations inherent to retrospective analy-
is, this report suffers from other potential limitations.
estenosis after RA-PTAS was defined by RDS criteria for
60% diameter-reducing stenosis in native RAs.23 This
ractice is supported by the authors’ recent experience,
st-surgery
8 24 30 36
31) (N=24) (N=14)
sis after primary percutaneous angioplasty and stenting
timated survival did not exceed 10%.
estimated GFR postrepair in patients with and without
No restenosis
P valueSE n Mean  SE
3.5 43 145.2  2.8 .911
2.2 34 72.2  1.8 .118
0.17 44 2.48  0.13 .249
3.0 41 49.1  2.3 .001s Po
1
(N=
tenoand
is
ean 
.7 
.6 
2 
.8 owever, this RDS criteria for restenosis after PTAS is not
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native RA stenosis is associated with high rates of false-
positive RDS studies after PTAS.38,39 The most common
explanation to support this latter view cites a decrease in the
arterial wall compliance after intraluminal stenting pre-
sumed to increase Doppler-derived RA-PSV estimates.31
Despite the likely change in compliance after intraluminal
stenting, the authors have observed the sensitivity of 73%
(95% CI, 54%-91%) and specificity of 80% (95% CI, 67%-
93%) for the RDS criteria applied in this report.23
CONCLUSIONS
In conclusion, RDS estimates of RA-PSV early after
PTAS are associated with RA restenosis. These data suggest
that detectable differences exist in RA flow parameters
following RA-PTAS that are predictive of restenosis during
follow-up but are not apparent on completion arteriogra-
phy or detectable by intra-arterial pressure measurements.
Should ongoing randomized prospective clinical trials that
compare RA-PTAS with best medical therapy prove that
catheter-based intervention is efficacious, RDS at the com-
pletion of PTAS in combination with angiography, pres-
sure measurements, and other yet-undefined modalities,
may have clinical utility as a completion study guiding
additional therapy.
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Dr Dennis Bandyk (San Diego, Calif). The Wake Forest
University vascular group suggests that renal duplex ultrasound
testing immediately following renal artery stent angioplasty can
predict the development of restenosis. But, is that the intent of
early duplex testing? The technical result of renal artery angioplasty
should be assessed by angiography, pressure-gradient measure-
ments, but also, by duplex ultrasound.
The authors chose to use peak systolic velocity 180 cm/s in
the stented segment as the criteria for restenosis. The study group
consisted of 92 treated arteries in 84 patients – 10 sites with a PSV
 180 cm/s were excluded. Only one-half of patients treated were
included in the duplex outcome analysis; an important limitation
of this study.
When an early (1 week) duplex testing was performed on
“technically successful” renal angioplasty sites; 10% demonstrated
elevated velocity of a residual stenosis; and in the remainder, PSV
velocity was increased in 38% of patients to indicate a restenosis had
developed. Development of restenosis correlated with elevated
preprocedure creatinine and the absence of bilateral disease, and
the authors concluded a PSV of 107 cm/s or greater predicted the
development of restenosis. I was not convinced by these findings
despite my bias that duplex surveillance after angioplasty is of
value: to exclude residual stenosis and identify hemodynamic fail-
ure of the angioplasty procedure.
My questions to the authors are:
(1) Did early duplex testing predict reintervention, and if so, whatfor significant restenosis – how often did a renal stent stenosis
of this severity occur?
2) Why exclude angioplasty sites with modest PSV elevation (ie,
250 cm/s)? In the 10 stents with a PSV 180 cm/s, how
many progressed and required reintervention?
3) Lastly, how do the authors suggest we use this information?
The authors have demonstrated a trend, but the predictive
value of their recommended duplex criteria is weak.
Dr Jason W. Christie. I will start with your last question first
egarding how to use the value of 107 cm/s, which is the optimal
utoff value on the ROC curve for predicting restenosis. Using that
alue to guide surveillance is not necessarily what we are proposing.
e were not proposing that velocity be used to help determine
hat you should do differently down the road in terms of surveil-
ance but rather to use that velocity to determine what you should
o differently at the time of the procedure. That could be repeating
n angioplasty or inserting IVUS to see if there is some other
echnical failure that is not evident on the traditional measures of
uccess such as digital subtraction angiography or intra-arterial
ressure measurements. Therefore, that is what that number
ould guide. In terms of the criteria for reintervention, we do not
se a specific duplex value to determine whether or not someone
ndergoes a reintervention. That is part of it, but then we only
eintervene if they have a physiologically significant restenosis with
schemic nephropathy or severe hypertension and if they derived a
enefit from the original intervention.
